Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1387158 10.3389/fphar.2024.1387158 Pharmacology Mini Review A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity Wang et al. 10.3389/fphar.2024.1387158 Wang Catherine K. 1 2 ‡ Kim Gio 1 2 ‡ Aleksandrova Lily R. 3 Panenka William J. 2 3 Barr Alasdair M. 1 2 * † 1 Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia (UBC), Vancouver, BC, Canada 2 British Columbia Mental Health and Substance Use Services Research Institute, Vancouver, BC, Canada 3 Department of Psychiatry, Faculty of Medicine, Canada Faculty of Pharmaceutical Sciences, UBC, Vancouver, BC, Canada

Edited by: Christina Dalla, National and Kapodistrian University of Athens, Greece

Reviewed by: Alexia Polissidis, Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece

 *Correspondence: Alasdair M. Barr, al.barr@ubc.ca

ORCID: Alasdair M. Barr, orcid.org/0000-0002-3407-1574

These authors have contributed equally to this work to this manuscript

 03 06 2024 2024 15 1387158 16 02 2024 02 05 2024 Copyright © 2024 Wang, Kim, Aleksandrova, Panenka and Barr. 2024 Wang, Kim, Aleksandrova, Panenka and Barr

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity. The PICO structure, PRISMA checklist and the Cochrane Handbook for systematic reviews of intervention were used to guide the search strategy. A scoping search was conducted in electronic databases PubMed, CINAHL, Embase and Web of Science. The literature search identified 50 relevant and suitable published studies. These included 19 different species of mushrooms, as well as seven different species of other fungi. Nearly all studies reported antidepressant-like effects of treatment with extracts. Treatments were most commonly delivered orally, in both acute and chronically administered studies to predominantly male rodents. Multiple animal models of depression were used, the most common being unpredictable chronic mild stress, while the tail suspension test and forced swim test were most frequently used as standalone antidepressant screens. Details on each experiment with mushroom and fungus species are discussed in detail, while an evaluation is provided of the strengths and weaknesses of these studies.

 animal model antidepressant fungus mushroom preclinical Natural Sciences and Engineering Research Council of Canada10.13039/501100000038 section-at-acceptance Neuropharmacology Introduction

Mood disorders remain among the most prevalent and disabling of all psychiatric conditions. They also represent one of the leading causes of worldwide disease burden (Friedrich, 2017; Collaborators, 2022). While many individuals affected by mood disorders respond well to treatment, a significant proportion of people show either partial or no response to antidepressant therapies (McLachlan, 2018). If an individual fails to respond to two or more trials of standard antidepressant pharmacotherapy, they may be considered “treatment-resistant” (Voineskos et al., 2020). Furthermore, many individuals may show a therapeutic response to antidepressant treatment but suffer side-effects that significantly reduce their quality of life (Teng et al., 2022), resulting in reduced treatment adherence (Hung, 2014; Rossom et al., 2016).

Clinical treatment options for those who do not respond well to standard antidepressant therapies have historically remained limited. However, in recent years, several landmark studies have reported that administration of psychedelic drugs under controlled conditions, typically in combination with psychotherapy, can significantly reduce depressive symptoms (Griffiths et al., 2016; Ross et al., 2016; Palhano-Fontes et al., 2019; Davis et al., 2021; Eisenstein, 2022; Goodwin et al., 2022). Importantly, this includes individuals with treatment-resistant depression (Carhart-Harris et al., 2016). Additionally, in clinical trials reported to-date, the side-effect profile of these compounds has appeared relatively benign (Eisenstein, 2022) with no evidence of some of the side-effects associated with other psychotropic medications, such as weight gain and metabolic dysregulation (Boyda et al., 2013; Boyda et al., 2021; Sepúlveda-Lizcano et al., 2023).

While the use of the term “psychedelic” has no official definition, it typically refers to a drug that is able to alter perception, thoughts, feelings and consciousness in humans (Hosanagar et al., 2021). Psychedelic drugs are commonly categorized as either “classical” or “atypical” (Kamal et al., 2023). The former category represents drugs with agonism or partial agonism at the serotonergic 5-HT2A receptor, and includes tryptamines (such as psilocybin and DMT), ergolines (such as LSD) and phenethylamines (such as mescaline) (Kelmendi et al., 2022). The atypical psychedelics have diverse mechanisms of action (Aleksandrova and Phillips, 2021), which are not primarily at the 5-HT2A receptor, and include drugs such as ketamine, ibogaine, muscimol and salvinorin A (Kelmendi et al., 2022). At this point, it is important to note that many compounds from both classes of psychedelic drugs have their origins in commonly available mushrooms and other fungi.

Mushrooms and other fungi

Mushrooms are generally defined as the spore-producing fruiting body of a fungus. Traditional medicine has used mushrooms, and fungi in general, in medical treatment for centuries (Yadav and Negi, 2021; Gravina et al., 2023), taking advantage of their numerous perceived therapeutic benefits. Such properties have been reported to include antimicrobial (Moussa et al., 2022), antibacterial, antioxidant, hepatoprotective (Venturella et al., 2021), and antitumor (Pandya et al., 2019) effects. More recently, researchers have investigated “medicinal” mushrooms as potential alternatives or complements to mainstream antidepressant treatments. For example, non-psychedelic species such as Hericium erinaceus and Ganoderma lucidum have been noted as having mood-improving qualities in humans (Nagano et al., 2010; Fijałkowska et al., 2022), although head-to-head trials comparing effects against standard antidepressant pharmacotherapies are lacking. Nevertheless, the increasing body of evidence which indicates that psilocybin (a psychedelic compound found in many species of mushrooms (Strauss et al., 2022)) has potent antidepressant effects, including in those with treatment-resistant depression (Haikazian et al., 2023; Simonsson et al., 2023), supports the notion that mushrooms and other fungi may hold significant therapeutic potential in this area. However, given the enormous number of potential species of mushroom and other fungi that could have antidepressant effects, measured against the tremendous costs associated with conducting clinical trials in humans, it is critical to determine which mushroom and fungus species and their derivatives represent the best preclinical leads for further development. In this context, it is vitally important to understand which species have already demonstrated efficacy in preclinical animal models of depression and specific screens for antidepressant activity. The purpose of the present scoping review is therefore to systematically identify which mushroom and fungus species have been tested for antidepressant effects in specific preclinical models, and to summarize and evaluate the results of these studies.

 Materials and methods

The PICO structure, PRISMA checklist and the Cochrane Handbook (Higgins and Green, 2011) for systematic reviews of intervention were used to guide the search strategy. A scoping search was conducted in electronic databases PubMed, CINAHL (via EBSCO), Embase (via Ovid), and Web of Science, as previously (Tse et al., 2014; Yuen et al., 2021; Lian et al., 2022). One preprint source was found as a suggestion under another article and later located on Google Scholar. The latest literature search was conducted on 19 December 2023.

A combination of 26 individual search terms were used with the following keywords: “mushroom” or “mushrooms” or “fungus” and “depress*” or “antidepress*” and “animal” or “animal model”. Filters excluding human studies or non-article sources were applied as needed. Searches were also conducted using specific behavioural models/tests or mushroom species as keywords. Studies were limited to those using rodent species as those reflect the expertise of the authors (Lu et al., 2005; Barr et al., 2006; Hill et al., 2007; Boyda et al., 2014); however, it is important to note that other species, such as zebrafish, represent additional valid animal models of antidepressant efficacy (Braun et al., 2024).

Studies were included if they met the following criteria: 1) studies tested a mushroom, fungus, or relevant mushroom derivative, and; 2) used a rodent model or behavioural test of depression or screen of antidepressant activity. Studies were excluded if they 1) were not published in English, or; 2) were not full text original research studies (i.e., conference abstracts, review papers).

A total of 546 articles were identified using Covidence (www.covidence.org), with 241 duplicates removed, leaving 305 articles to be screened. After title and abstract screening, 237 were deemed irrelevant, leaving 68 studies for eligibility assessment. After full text review, 18 studies were excluded, leaving 50 studies in the final database. Figure 1 outlines a PRISMA flowchart of the study selection process.

Literature review flow process.

Abstracts and full texts were screened by GK and CKW. Data was extracted independently by GK and CKW with key variables extrapolated and outlined in Supplementary Table S1. Any discrepancies throughout the process were brought to consensus by GK and CKW with the assistance of AMB if required.

 Results

The literature search identified 50 relevant and suitable published studies. These included 19 different species of mushrooms see Table 1, as well as seven different species of other fungi see Table 2; there were also three studies that used compounds which are common to multiple mushroom species.

Summary of rodent depression models and behavioural tests used to screen for antidepressant effects in different mushroom species. Subchronic and chronic treatment schedules include daily administration of drug unless otherwise stated.

Route Treatment duration Extraction method Rodent species Strain Sex Sample size Behavioural test or model Test duration Test frequency Doses tested Combined with Other notes Reference number
Hericium erinaceus
Food Chronic (92 d) Methanol Rat Wistar Female Sham (n = 11)OVX Model (n = 11)OVX + HE (n = 10)OVX + E2 (n = 8) OVX 96 d Once n/a n/a Models menopausal depression Anuar et al. (2022)
FST 5 min OVX Model*1%#
p.o. Chronic (28 d) Ethanol Mouse ICR Male n = 10 per groupControlCRS ModelCRS + HE (Low, Medium, High) CRS 14 d 2 h daily n/a Erinacine A Mycelium Chiu et al. (2018)
FST 5 min Once CRS Model***100 mg/kg200 mg/kg## 400 mg/kg##
TST
i.p. Chronic (28 d) Ethanol Mouse C57BL/6 Male n = 76 in total CRS 14 d 6 h daily n/a# n/a n/a Chong et al. (2021)
SPT 2 h Once CRS Model***10 mg/kg## 25 mg/kg##
TST 5 min CRS Model*10 mg/kg25 mg/kg##
s.c. Chronic (21 d) Alcohol Mouse SAMP8, BALB/C Male n = 8 per groupCORT ModelCORT + (Low, Medium, High)CORT + Fluoxetine CORT 21 d Daily 40 mg/kg Chlorella 0.1 mL chlorella + 6 mg HE0.2 mL chlorella + 12 mg HE0.4 mL chlorella + 24 mg HE Chou et al. (2022)
p.o. FST Last 4 min of 6 min Once CORT Model0.25 mL/25 g0.5 mL/25 g# 2.5 mL/25 g#
p.o. Chronic (9 d) n/a Mouse C57BL/6 Male n = 6ControlLow doseHigh dose TST 15 min Daily for 9 d 75 mg/kg150 mg/kg% immobility increased daily over 9 d period n/a Mycelium; Uses TST-induced depression model, not screen Li et al. (2021b)
p.o. Chronic (28 d) Ethanol Mouse C57BL/6 Male n/aControlHE (Low, High) FST Last 4 min of 6 min Once 20 mg/kg*60 mg/kg* n/a n/a Ryu et al. (2018)
TST
i.p. Subchronic (1 d) n/a Mouse C57BL/6N Male n = 11–12 per groupControlControl + AmycenoneLPS ModelLPS + Amycenone LPS 1 d Once n/a n/a Amycenone: hericenones/hericium isolates (0.5%) and amyloban (6%)Use LPS to induce depression Yao et al. (2015)
p.o. FST 6 min Non-LPS 200 mg/kg LPS LPS Model**200 mg/kg#
TST 10 min Non-LPS 200 mg/kg LPS LPS Model***200 mg/kg##
Ganoderma lucidum
p.o. Chronic (28 d) Ethanol Rat Sprague-Dawley Male n = 8 per groupControlUCMS ModelUCMS + Gl-E (Low, Medium, High)UCMS + Fluoxetine UCMS 28 d Daily n/a n/a Preprint; not peer-reviewed Cheng (2023)
SPT 3 h Once UCMS Model***0.02 g/kg0.1 g/kg# 0.5 g/kg##
p.o. Chronic (28 d) Ethanol Mouse Swiss Albino Both n = 5 per groupControlEEGL (Low, Medium, High) FST Last 4 min of 6 min Once Male 100 mg/kg*200 mg/kg**400 mg/kg** Female 100 mg/kg*200 mg/kg*400 mg/kg** n/a n/a Ezurike et al. (2023)
Chronic (29 d) TST Male 100 mg/kg*200 mg/kg**400 mg/kg** Female 100 mg/kg*200 mg/kg*400 mg/kg*
i.p. n/a n/a Mouse C57BL/6 Male SPT: n = 7 per groupTST: n = 8–10 per groupFST: n = 9–10 per groupControlControl + GLP (Low, Medium, High)CSDS ModelCSDS + GLP (Medium)Imipramine CSDS 10 d 5–10 min daily n/a n/a Polysaccharide Li et al. (2021a)
SPT 2 h Once CSDS Model***
Subchronic (5 d) FST Last 4 min of 6 min Non-CSDS 1 mg/kg5 mg/kg***12.5 mg/kg CSDS 5 mg/kg###
Acute (60 min) TST Non-CSDS 1 mg/kg5 mg/kg*12.5 mg/kg CSDS 5 mg/kg#
p.o. Acute (60 min) Water Rat Sprague-Dawley Male Control (n = 8)MAK (Low, High) (n = 6)Imipramine (n = 5) FST 5 min Once 0.3 g/kg1 g/kg* n/a Mycelium Matsuzaki et al. (2013)
i.p. Chronic (21 d) Ethanol + Ethyl Acetate Mouse C57BL/6J Male n = 11–13 per groupControlControl + GLTMS ModelMS + GLT MS 21 d 4 h daily n/a n/a Triterpenoids Mi et al. (2022)
SPT 24 h Once Non-MS 40 mg/kg MS MS Model****40 mg/kg####
FST 6 min Non-MS 40 mg/kg MS MS Model****40 mg/kg###
TST Non-MS 40 mg/kg MS MS Model*40 mg/kg#
Splash Test 5 min Non-MS 40 mg/kg MS MS Model****40 mg/kg####
Nest Building 24 h Non-MS 40 mg/kg MS MS Model***40 mg/kg####
p.o. Subchronic (3 d) Water Rat Wistar Male n = 6–9 per groupControlBinge Drinking (EtOH) ModelBinge + AEGI Binge Drinking 35 d Weekly (daily administration for 3 consecutive days) n/a n/a Models binge drinking induced depression Nascimento et al. (2020)
FST Last 3 min of 5 min Once Binge Drinking Model****0.1 mL/100 g##
p.o. Acute (60 min) Petroleum Ether, Chloroform, Methanol, and WaterMethanol → Ethyl Acetate, n-Butanol, and Methanol fractions Mouse Swiss Albino Male n = 6 per group Control Extracts Pet. Ether (Low, Medium, High)Chloroform (Low, Medium, High)Methanol (Low, Medium, High)Aqueous (Low, Medium, High)Imipramine Fractions E: Ethyl Acetate (Very Low, Low, Medium) N: n-Butanol (Very Low, Low, Medium) MF: Methanol-soluble fraction (Low, Medium, High)Imipramine FST Last 4 min of 6 min Once Extracts 100 mg/kg*200 mg/kg*400 mg/kg* (for all extracts) Fractions 50 mg/kg – E*, N* 100 mg/kg – E*, N, MF* 200 mg/kg – E*, N*, MF* 400 mg/kg – MF* n/a n/a Singh et al. (2021)
i.g. Acute (30 min) Water Mouse Swiss Albino Male n = 11–12 per groupControl G. lucidum extract (Very Low, Low, Medium, High) FST Last 4 min of 6 min Once 50 mg/kg100 mg/kg**200 mg/kg***400 mg/kg*** n/a Mycelium Socala et al. (2015)
p.o. Chronic (28 d) Water Mouse C57BL/6 Male n = 10 per groupControlControl + PGL (Low, Medium, High)UCMS ModelUCMS + PGL (Low, Medium. High)UCMS + Fluoxetine UCMS 56 d Daily n/a n/a Spore polysaccharide-peptide Zhao et al. (2021)
SPT 24 h Once UCMS Model**100 mg/kg# 200 mg/kg## 400 mg/kg##
Acute (1 h)Chronic (28 d) FST Last 4 min of 6 min Acute 100 mg/kg200 mg/kg*400 mg/kg** Chronic UCMS Model100 mg/kg## 200 mg/kg## 400 mg/kg##
Acute (1 h) TST 100 mg/kg200 mg/kg**400 mg/kg**
Ganoderma applanatum
p.o. Acute (30 min) Ethanol and Water Mouse Swiss Albino Both n = 5 per groupControlEthanol (Low, High)Aqueous (Low, High)Diazepam [i.p.] TST 6 min Once Ethanol 200 mg/kg400 mg/kg Aqueous 200 mg/kg400 mg/kg n/a n/a Hossen et al. (2021)
p.o. Acute (60 min) Petroleum Ether, Chloroform, Methanol, and Water Mouse Swiss Albino Male n = 6 per groupControl Extracts Pet. Ether (Low, Medium, High)Chloroform (Low, Medium, High)Methanol (Low, Medium, High)Aqueous (Low, Medium, High)Imipramine FST Last 4 min of 6 min Once Extracts 100 mg/kg*200 mg/kg*400 mg/kg* (for all extracts) n/a n/a Singh et al. (2021)
Ganoderma philippii
p.o. Acute (60 min) Petroleum Ether, Chloroform, Methanol, and Water Mouse Swiss Albino Male n = 6 per groupControl Extracts Pet. Ether (Low, Medium, High)Chloroform (Low, Medium, High)Methanol (Low, Medium, High)Aqueous (Low, Medium, High)Imipramine FST Last 4 min of 6 min Once Extracts 100 mg/kg*200 mg/kg*400 mg/kg* (for all extracts) n/a n/a Singh et al. (2021)
Ganoderma brownii
p.o. Acute (60 min) Petroleum Ether, Chloroform, Methanol, and Water Mouse Swiss Albino Male n = 6 per groupControl Extracts Pet. Ether (Low, Medium, High)Chloroform (Low, Medium, High)Methanol (Low, Medium, High)Aqueous (Low, Medium, High)Imipramine FST Last 4 min of 6 min Once Extracts 100 mg/kg*200 mg/kg*400 mg/kg* (for all extracts) n/a n/a Singh et al. (2021)
Ganoderma sp.
i.v. Chronic (21 d) n/a Rat Sprague-Dawley Male Sham (n = 8)MCAO (n = 7)PSD Model (n = 7)PSD + GAA (Low, Medium, High)(n = 8) PSD (UCMS) 21 d Daily n/a n/a Ganoderic acid (triterpenoid)Performs MCAO to induce stroke conditionsUse UCMS to establish PSD Zhang et al. (2021a)
SPT 3 h Once PSD Model^^10 mg/mL20 mg/mL# 30 mg/mL## ^^p < 0.01 v.s. MCAO group
Grifola frondosa
Food Subchronic:Cohort 1 (5 d)Cohort 2 (1 d)Cohort 3 (5 d) n/a Mouse CD-1 Male Cohort 1 (n = 14 per group)Cohort 2 (n = 14 per group)Cohort 3 (n = 10–11 per group) For each cohort: ControlLowMediumHighImipramine FST Last 4 min of 6 min Once 1:4 GF:chow**1:2 GF:chow**1:1 GF:chow*** n/a Tested with multiple cohorts Bao et al. (2017)
Subchronic:Cohort 1 (1 d)Cohort 2 (5 d)Cohort 3 (1 d) Cohort 1 (n = 14 per group)Cohort 2 (n = 13 per group)Cohort 3 (n = 11 per group) For each cohort: ControlLowMediumHighImipramine TST 1:4 GF:chow*1:2 GF:chow**1:1 GF:chow**
Psilocybe cubensis
p.o. (whole)i.p. (extracts) Acute (30 min) Methanol and Water Mouse Swiss Webster Male n ≥ 7 per groupControlWhole Mushroom (Very High)Methanol (Low, Medium, High)Aqueous (Low, Medium, High)Fluoxetine [s.c.]Imipramine [i.p.] FST 5 min Once Whole Mushroom 1000 mg/kg* Methanol 1 mg/kg10 mg/kg**100 mg/kg*** Aqueous 1 mg/kg**10 mg/kg***100 mg/kg*** n/a n/a Hernandez-Leon et al. (2024)
i.p. Acute (30 min) Chloroform Mouse NMRI Male n = 8 per groupControlPCE (Low, High)PCE (Low) + KetaminePCE (High) + KetamineKetamineFluoxetine FST Last 4 min of 6 min Once 10 mg/kg40 mg/kg For PCE (10 mg/kg):PCE + Ketamine (1 mg/kg)*** For PCE (40 mg/kg):PCE + Ketamine (1 mg/kg)*** Ketamine Alkaloid extract Mahmoudi et al. (2018)
TST
Pleurotus eryngii
p.o. Chronic (84 d) Ethanol Rat Wistar Female Sham (n = 10)OVX Model (n = 10)OVX + P. eryngii (n = 8) OVX 84 d Once n/a n/a Models menopausal depression Minami et al. (2013)
Chronic (79 d) FST 6 min Once OVX Model*500 mg/kg#
i.p. Acute (30 min) Ethanol Mouse n/a n/a n = 4 per groupControlEtOH ExtractMixture (pellet)R2 FractionFluoxetine FST 4 min Once EtOH Extract*Mixture (pellet)**R2 Fraction*(all 20 mg/kg) n/a EtOH Extract → Pellet → R2: fractions increase in purification levels Park et al. (2021)
Pleurotus ostreatus
Food Subchronic (5 d) n/a Mouse CD-1 Male Control (n = 11)PO (n = 11)Imipramine (n = 10–11) FST Last 4 min of 6 min Once 1:2 PO:chow n/a n/a Bao et al. (2017)
Subchronic (1 d) TST
Pleurotus citrinopileatus
Food Chronic (21 d) n/a Mouse C57BL/6J Male Control (n = 6)Control + 10% (n = 8)CRS Model (n = 8)CRS + 10% (n = 8) CRS 21 d 4 h daily n/a n/a Antioxidant ergothioneine (ERGO) and golden oyster mushroom extract (GOME) Nakamichi et al. (2016)
Chronic (14 d) Control (n = 11)10% GOME (n = 11)ERGO (n = 6) Ginkgo biloba extract (n = 6) FST 5 min Once 10% GOME*120 mg/100 g ERGO*
Control (n = 15)0.1% GOME (n = 6)0.3% GOME (n = 6)1% GOME (n = 12)10% GOME (n = 15) TST First 2 min of 3 min 0.1%0.3%1%*10%*
Marasmius androsaceus
p.o. Subchronic (7 d) n/a Mouse Kunming Male n = 8 per groupControlMEPS1 (High)MEPS2 (Medium)MEPS3 (Low) FST 6 min Once 180 mg/kg60 mg/kg*30 mg/kg n/a Extracellular polysaccharide Song et al. (2020)
TST 5 min 180 mg/kg*60 mg/kg**30 mg/kg
p.o. Chronic (28 d) n/a Rat Sprague-Dawley Male n = 10 per groupControlUCMS ModelUCMS + MEPS (Low, Medium, High) UCMS 56 d Daily n/a n/a Exopolysaccharides Song et al. (2017)
SPT 1 h Weekly for 7 weeks UCMS Model**6 mg/kg30 mg/kg# 150 mg/kg## Model: significant from day 14 to day 56 MEPS: 30 mg/kg and 150 mgm/kg significant from day 49 to day 56
FST Last 5 min of 6 min Once UCMS Model***6 mg/kg# 30 mg/kg### 150 mg/kg###
TST UCMS Model***6 mg/kg30 mg/kg### 150 mg/kg###
p.o. Subchronic (7 d) n/a Mouse Kunming Both n = 10 per groupControlMEPS (Low, Medium, High)Fluoxetine [i.g.] FST Last 5 min of 6 min Once 10 mg/kg50 mg/kg250 mg/kg* n/a Exopolysaccharide Song et al. (2016)
TST 6 min 10 mg/kg50 mg/kg*250 mg/kg***
i.g. Chronic (14 d) n/a Mouse C57BL/6J Male n = 8 per groupIRCRS ModelCRS + M IR + Dp (CRS) 21 d 4 h daily n/a n/a MyceliumMice were irradiated with 13 Gy TAI to induce intestinal radiation injuryCRS was used to induce depression Zhao et al. (2023)
FST Last 4 min of 6 min Once CRS Model+++ CRS + M## +++p < 0.001 v.s. IR group
TST CRS Model++ CRS + M## ++p < 0.01 v.s. IR group
Collybia maculata
i.p. Acute (immediate) n/a Mouse C57BL/6J Male n = 7–10 per groupVehicleColly FST 6 min Once 2 mg/kg n/a Colly: non-nitrogenous sesquiterpene of C. maculata Gupta et al. (2016)
Poria cocos
p.o. Chronic (35 d) Water Rat Sprague-Dawley Male n = 7 per groupControlControl + PCW (Low, Medium, High)UCMS ModelUCMS + PCW (Low, Medium, High) UCMS 35 d Daily n/a n/a Sclerotium Huang et al. (2020)
Chronic (35 d) SPT 1 h Weekly for 5 weeks UCMS Model*100 mg/kg# 300 mg/kg# 900 mg/kg(After 4 weeks)
Chronic (28 d) FST 5 min Once 100 mg/kg*300 mg/kg*900 mg/kg*
Lentinula edodes
p.o. Acute (2 h)Chronic (14 d) n/a Mouse ICR Male n = 5 per groupControlPilopool FST Last 4 min of 6 min Once Acute 10 mL/kg* Chronic 10 mL/kg Pilopool mixture:30% of L. edodes/shiitake extract +30% water-soluble chitosan, 30% Allium sativum L. extract, 0.5% of Dioscorea batatas D., and 0.5% of bamboo salt n/a Koo et al. (2008)
Armillaria mellea
p.o. Chronic (35 d) Water Rat Sprague-Dawley Male n = 7 per groupControlUCMS ModelUCMS + WAM (Low, Medium, High)UCMS + Fluoxetine UCMS 35 d Daily n/a n/a n/a Lin et al. (2021a)
Chronic (34 d) SPT 1 h Once UCMS Model**250 mg/kg# 500 mg/kg# 1000 mg/kg#
Chronic (30 d) FST 5 min 250 mg/kg#### 500 mg/kg#### 1000 mg/kg####
i.p. Acute (30 min) Ethyl Acetate Mouse ICR Male n = 10 per groupControlPSAM (Lowest, Very Low, Low, Medium, High, Very High, Highest)Fluoxetine FST Last 4 min of 6 min Once 0.05 mg/kg0.1 mg/kg0.5 mg/kg*1 mg/kg*5 mg/kg*20 mg/kg50 mg/kg n/a Protoilludane sesquiterpenoid aromatic esters Zhang et al. (2021b)
TST 0.05 mg/kg0.1 mg/kg0.5 mg/kg*1 mg/kg**5 mg/kg*20 mg/kg*50 mg/kg For PSAM (0.1 mg/kg): PSAM + Fluoxetine (5 mg/kg)*PSAM + Reboxetine (2.5 mg/kg)** FluoxetineReboxetine
Agaricus brasiliensis
p.o. Chronic (30 d) Water Mouse Kunming Male n = 10 per groupControlUCMS ModelUCMS + AWE UCMS 28 d Daily n/a n/a n/a Xin et al. (2022)
TST Last 5 min of 6 min Once UCMS Model*3 g/kg#
Xylaria sp.
i.g. Chronic (28 d) n/a Rat Sprague-Dawley Male n = 6–9 per groupControlUCMS ModelUCMS + Wuling powder (Low, Medium, High)UCMS + Fluoxetine UCMS 42 d Daily n/a n/a Wuling mycelia powder Tan et al. (2016)
SPT 1 h Weekly for 6 weeks UCMS Model***0.5 g/kg# 1 g/kg### 2 g/kg### Model: significant from week 2 to week 6 Wuling: significant from week 6
Antrodia cinnamomea
p.o. Chronic (16 d) n/a Mouse Kunming Both n = 24 per groupControlAC (Low, Medium, High) Weight-loaded FST n/a Once 0.1 g/kg0.3 g/kg**0.9 g/kg** n/a MyceliumDoes not focus on depression nor use valid screen Liu et al. (2017b)
Mushrooms (General)
i.p. Acute (60 min) n/a Mouse ICR Male n = 10 per groupEr, ErF, ErS, ErN (Low, High)ErN (Very Low, Low, Medium, High)FluoxetineEr (Low) + FluoxetineEr (Low) + TianeptineEr (Low) + Reboxetine FST Last 4 min of 6 min Once All derivatives: 5 mg/kg – Er*, ErF*, ErS*, ErN** 20 mg/kg – Er*, ErF*, ErS*, ErN** ErN: 0.1 mg/kg*0.5 mg/kg1 mg/kg*5 mg/kg** For ErN (0.5 mg/kg): ErN + Fluoxetine (5 m/g/kg)ErN + Tianeptine (15 mg/kg)**ErN + Reboxetine (2.5 mg/kg)** FluoxetineTianeptineReboxetine Ergosterol and derivatives Lin et al. (2017)
i.g. Subchronic (1 d) Injected 3 times (23.5 h, 5 h, and 1 h prior to test) n/a Rat Long Evans Male n = 10 per groupControlPsilocybinBaeocystinNorbaeocystinAeruginascinFluoxetine FST 5 min Once Psilocybin*BaeocystinNorbaeocystin*Aeruginascin(all 1 mg/kg) n/a Baeocystin, norbaeocystin, aeruginascin: tryptamine alkaloids and analogs of psilocybinPreprint; not peer-reviewed Rakoczy et al. (2023)
s.c. Subchronic (3 d) n/a Mouse ICR Male n = 10 per groupControlCORT ModelCORT + p-CA CORT 23 d Daily 20 mg/kg n/a P-Coumaric acid (p-CA) Yu et al. (2022)
i.p. SPT 24 h Once CORT Model***75 mg/kg###
FST Last 4 min of 6 min CORT Model*75 mg/kg#

*p < 0.05, **p < 0.01, ***p <0.001, ****p < 0.0001 compared to control.

# p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 compared to model/vehicle.

Acute (< 1 d), Subchronic (1–7 d), Chronic (> 7 d).

Abbreviations: FST = forced swim test; TST = tail suspension test; OVX = ovariectomy; UCMS = unpredictable chronic mild stress; CORT = corticosterone; SPT = sucrose preference test; CRS = chronic restraint stress; CSDS = chronic social defeat stress; PSD = post-stroke depression; MS = maternal separation; LPS = lipopolysaccharide; MCAO = middle cerebral artery occlusion; HE = Hericium erinaceus; Gl-E = Ganoderma lucidum extract; EEGL = ethanol extract of Ganoderma lucidum; GLP = Ganoderma lucidum polysaccharide; MAK = Ganoderma lucidum mycelia; GLT = Ganoderma lucidum triterpenoid; AEGI = aqueous extract of Ganoderma lucidum; PGL = Polysaccharide-peptide of Ganoderma lucidum; GAA = Ganoderic acid; PCE = Psilocybe cubensis extract; PO = Pleurotus ostreatus; EtOH = ethanol; MEPS = exopolysaccharide polysaccharide of Marasmius androsaceus; PCW = Poria cocos water extract; WAM = water extract of Armillaria mellea; PSAM = Protoilludane sesquiterpenoid aromatic esters from Armillaria mellea; AWE = Agaricus brasiliensis water extract; AC = Antrodia cinnamomea; Er = Ergosterol; IR = intestinal radiation; E2 = 17β-estradiol; Dp = depression; i.p. = intraperitoneal; p.o. = per os (oral); i.g. = intragastric; s.c. = subcutaneous; i.v. = intravenous.

Summary of rodent depression models and behavioural tests used to screen for antidepressant effects in different non-mushroom species of fungi. Subchronic and chronic treatment schedules include daily administration of drug unless otherwise stated.

Cordyceps militaris
p.o. Chronic (34 d) Water Rat Sprague-Dawley Male n = 6 per groupControlUCMS ModelUCMS + CW (Low, Medium, High)UCMS + Fluoxetine UCMS 34 d Daily n/a n/a n/a Lin et al. (2021b)
SPT 1 h Once UCMS Model***125 mg/kg### 250 mg/kg# 500 mg/kg#
i.g. Chronic (42 d) n/a Mouse ICR Male n = 20 per groupControlUCMS ModelUCMS + COR (Low, High)UCMS + Fluoxetine UCMS 42 d Daily n/a n/a Cordycepin (3'-deoxyadenosine): component of C. militaris Tianzhu et al. (2014)
SPT 12 h Twice (Weeks 3 and 6) Week 3 UCMS Model20 mg/kg40 mg/kg Week 6 UCMS Model**20 mg/kg## 40 mg/kg##
FST Last 4 min of 6 min Once UCMS Model**20 mg/kg# 40 mg/kg##
TST Twice (Weeks 3 and 6) Week 3 UCMS Model20 mg/kg40 mg/kg Week 6 UCMS Model**20 mg/kg## 40 mg/kg##
i.g. Chronic (28 d) Water Mouse Kunming Male n = 12 per groupControlPCM (Low, Medium, High) Weight-loaded FST n/a Once 40 mg/kg*80 mg/kg*160 mg/kg* n/a PolysaccharideDoes not focus on depression nor use valid screen Xu (2016)
Cordyceps sinensis
p.o. Subchronic (5 d) Supercritical Fluid and Hot Water Mouse C57BL/6 Male n = 17 per groupControlSupercritical (Low, Medium, High)Aqueous (Low, Medium, High) TST 6 min Once Supercritical 2.5 mL/kg5 mL/kg*10 mL/kg* Aqueous 500 mg/kg1000 mg/kg2000 mg/kg n/a n/a Nishizawa et al. (2007)
p.o. Chronic (30 d) n/a Mouse Swiss Albino Both n = 6 per groupControlNatural C. sinensis (Low, Medium, High)Lab-cultured Mycelia (Low, Medium, High)Fluoxetine Photoactometer n/a Once NC 100 mg/kg300 mg/kg*500 mg/kg* LCM 100 mg/kg300 mg/kg*500 mg/kg* n/a Mycelium Singh et al. (2014)
Paecilomyces tenuipes
p.o. Chronic (28 d) Water Rat Sprague-Dawley Male n = 10 per groupControlUCMS ModelUCMS + PTNE (Low, Medium, High)UCMS + Fluoxetine UCMS 56 d Daily n/a n/a Cultured mycelium Liu et al. (2017a)
FST Last 5 min of 6 min Once UCMS Model***0.04 g/kg## 0.2 g/kg### 1 g/kg###
p.o. Chronic (21 d) Alcohol and Water Mouse n/a Male n = 10 per groupControlControl + AE (Low, Medium, High)Control + WE (Low, Medium, High)Control + FluoxetineUCMS ModelUCMS + AE (Low, Medium, High)UCMS + WE (Low, Medium, High)UCMS + Fluoxetine UCMS 21 d Daily n/a n/a Mutant P. tenuipes strain M98Mycelium Li et al. (2019)
SPT 1 h Once UCMS UCMS Model* Alcohol 0.05 g/kg0.25 g/kg2.5 g/kg# Water 0.04 g/kg0.2 g/kg2 g/kg#
Chronic (15 d), Chronic (21 d; UCMS) FST Last 4 min of 6 min Non-UCMS Alcohol 0.05 g/kg0.25 g/kg2.5 g/kg* Water 0.04 g/kg0.2 g/kg2 g/kg** UCMS UCMS Model* Alcohol 0.05 g/kg0.25 g/kg2.5 g/kg# Water 0.04 g/kg# 0.2 g/kg2 g/kg#
TST Non-UCMS Alcohol 0.05 g/kg*0.25 g/kg2.5 g/kg Water 0.04 g/kg*0.2 g/kg2 g/kg* UCMS UCMS Model* Alcohol 0.05 g/kg0.25 g/kg2.5 g/kg Water 0.04 g/kg0.2 g/kg# 2 g/kg#
Paecilomyces hepiali
p.o. Chronic (28 d) Water Rat Sprague-Dawley Male n = 6 per groupControlUCMS ModelUCMS + PHC (Low, Medium, High)UCMS + Fluoxetine UCMS 56 d Daily n/a n/a n/a Wang et al. (2017)
SPT 2 h Once UCMS Model**0.08 g/kg0.4 g/kg# 2 g/kg##
FST Last 5 min of 6 min UCMS Model*0.08 g/kg# 0.4 g/kg2 g/kg##
Ophiocordyceps formosana
i.p. Subchronic (5 d) n/a Mouse C57BL/6 Male Control (n = 6)STZ Model (n = 8)STZ + OFE (n = 8)STZ + Rosiglitazone (n = 8) STZ 5 d Daily 40 mg/kg n/a Uses STZ to induce diabetesModels diabetes-induced depression Huang et al. (2016)
p.o. Chronic (28 d) TST 6 min Once STZ Model*25 mg/mL#
Penicillium sp.
i.p. Acute (30 min) n/a Mouse ICR Male n = 8 per group 36 groups Control2a–2i3a–3r4a–4gFluoxetine FST Last 4 min of 6 min Once 0.1 mL/20 g**28 compounds showed significant antidepressant effect (26.23% – 89.96% decrease in immobility time vs. control) n/a Compounds are derivatives of P. sp. Jin et al. (2019)
Beauveria sp.
i.g. Chronic (21 d) n/a Mouse Kunming Male n = 10 per groupControlUCMS ModelUCMS + BCEF (Low, Medium, High)UCMS + Moclobemide UCMS 21 d Daily n/a n/a BCEF0083: bioactive compound Zhou et al. (2005)
SPT 24 h Once UCMS Model**25 mg/kg## 50 mg/kg## 100 mg/kg##

p < 0.05, **p < 0.01, ***p <0.001, ****p < 0.0001 compared to control

p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 compared to model/vehicle

Acute (< 1 d), Subchronic (1–7 d), Chronic (> 7 d)

Abbreviations: FST = forced swim test; TST, tail suspension test; UCMS, unpredictable chronic mild stress; SPT, sucrose preference test; STZ, streptozotocin(-induced diabetes); CW, Cordyceps militaris water extract; COR, Cordycepin; PCM = polysaccharide of Cordyceps militaris; PTNE = Paecilomyces tenuipes N45 aqueous extract; AE, alcohol extract; WE, water extract; PHC, Paecilomyces hepiali extract; OFE, Ophiocordyceps formosana extract; BCEF = bioactive compound from entomogenous fungi; i.p. = intraperitoneal; p.o. = per os (oral); i.g. = intragastric.

 Characteristics of animals used and drug administration

The species used in all of the animal models were limited to rats and mice: we did not find instances of other rodent species that have been utilized as antidepressant screens (Kramer et al., 1998; Alo et al., 2019). Fourteen of the studies used rats (Matsuzaki et al., 2013; Minami et al., 2013; Tan et al., 2016; Liu C. et al., 2017; Song et al., 2017; Wang et al., 2017; Huang et al., 2020; Nascimento et al., 2020; Lin et al., 2021a; Zhang L. et al., 2021; Lin et al., 2021b; Anuar et al., 2022; Cheng, 2023; Rakoczy et al., 2023), while the remaining 36 studies used mice to test for antidepressant-like effects (Zhou et al., 2005; Nishizawa et al., 2007; Koo et al., 2008; Singh et al., 2014; Tianzhu et al., 2014; Socala et al., 2015; Yao et al., 2015; Gupta et al., 2016; Huang et al., 2016; Nakamichi et al., 2016; Song et al., 2016; Xu, 2016; Bao et al., 2017; Liu Y. et al., 2017; Lin et al., 2017; Chiu et al., 2018; Mahmoudi et al., 2018; Ryu et al., 2018; Jin et al., 2019; Li et al., 2019; Song et al., 2020; Li H. et al., 2021; Li TJ. et al., 2021; Zhang T. et al., 2021; Chong et al., 2021; Hossen et al., 2021; Park et al., 2021; Singh et al., 2021; Zhao et al., 2021; Chou et al., 2022; Mi et al., 2022; Xin et al., 2022; Yu et al., 2022; Ezurike et al., 2023; Zhao et al., 2023; Hernandez-Leon et al., 2024). In terms of strains, 10 of the rat studies used Sprague-Dawley, three included Wistar and one used Long-Evans rats. For the mice studies, the most commonly used strain was the C57BL/6 strain and sub-strains (12 studies), followed by Institute for Cancer Research mice (seven studies), Swiss Albino and Kunming mice (six studies each) and one study each with BALB/c, CD1, Swiss Webster and NMRI strains. Two studies did not mention the specific strains used (Li et al., 2019; Park et al., 2021). The overwhelming majority of rat studies used male rats (12 studies) compared to female rats (two studies (Minami et al., 2013; Anuar et al., 2022)). All mice studies utilized males, most of which included males only, while five studies used both male and female mice (Singh et al., 2014; Song et al., 2016; Liu Y. et al., 2017; Hossen et al., 2021; Ezurike et al., 2023), and one study did not specify sex (Park et al., 2021). Thus, only 14% of studies used female animals in their investigation.

Administration of mushroom or fungus derivatives to animals was mostly through a single route of administration, although a handful of studies used two different routes of administration (Yao et al., 2015; Huang et al., 2016; Chou et al., 2022; Yu et al., 2022; Hernandez-Leon et al., 2024). The most common route of administration was oral (per os, p.o.), which accounted for more than 50% of studies (29 of 55 instances of administration). Second most common was treatment by intraperitoneal (i.p.) injection (13 instances), followed by intragastric (i.g.) administration (7 instances). Extracts were administered to animals in their food in three separate studies (Nakamichi et al., 2016; Bao et al., 2017; Anuar et al., 2022), by subcutaneous (s.c.) injection in two studies (Chou et al., 2022; Yu et al., 2022), and by intravenous (i.v.) administration in one study (Zhang L. et al., 2021).

The methods of extraction of mushroom and fungus derivatives was reported in 28 studies. Methods included use of both polar and non-polar solvents, with the most common ones including water and various alcohols. For many of the studies where complex extraction procedures were involved, including with non-polar solvents, it was not possible to determine if the extracts that were administered to animals also contained traces of these solvents (e.g., (Singh et al., 2021)), which could feasibly have an effect on behaviour.

The duration of drug treatment varied significantly across the studies, from acute doses with behavioural testing 30 min later (Socala et al., 2015; Mahmoudi et al., 2018; Jin et al., 2019; Zhang T. et al., 2021; Hossen et al., 2021; Park et al., 2021; Hernandez-Leon et al., 2024), up to 92 days of continuous administration (Anuar et al., 2022). Of the 50 studies, 13 were acute (treatment over a span of <24 h) (Matsuzaki et al., 2013; Socala et al., 2015; Yao et al., 2015; Gupta et al., 2016; Lin et al., 2017; Mahmoudi et al., 2018; Jin et al., 2019; Zhang T. et al., 2021; Hossen et al., 2021; Park et al., 2021; Singh et al., 2021; Rakoczy et al., 2023; Hernandez-Leon et al., 2024), six were sub-acute (1–7 days) (Nishizawa et al., 2007; Song et al., 2016; Bao et al., 2017; Nascimento et al., 2020; Song et al., 2020; Yu et al., 2022), and the remaining 31 studies involved chronic treatment (>7 days). The mean duration of treatment for the chronic studies was 30.4 (±16.7) days for the longest treated group in each study (some studies had varying durations of treatment depending on the group). The modal and median periods of treatment for chronic studies were both 28 days. Rats were more likely to be treated chronically, with only two of the 14 rat studies involving acute treatment (Matsuzaki et al., 2013; Rakoczy et al., 2023).

 Animal models of depression and tests of antidepressant activity

A variety of animal models of depression and antidepressant screens were used to examine mushroom and fungus antidepressant efficacy. By far the most common animal model used to induce a depressive-like phenotype in rodents was the unpredictable chronic mild stress paradigm (UCMS), with 14 studies implementing this model (Zhou et al., 2005; Tianzhu et al., 2014; Tan et al., 2016; Liu C. et al., 2017; Song et al., 2017; Wang et al., 2017; Li et al., 2019; Huang et al., 2020; Lin et al., 2021a; Zhang L. et al., 2021; Lin et al., 2021b; Zhao et al., 2021; Xin et al., 2022; Cheng, 2023); rats were used in the majority (9) of these studies. The second most frequent model involved the use of chronic restraint stress, in four mouse studies (Nakamichi et al., 2016; Chiu et al., 2018; Chong et al., 2021; Zhao et al., 2023). Two rat studies used ovariectomy procedures to model menopausal depression (Minami et al., 2013; Anuar et al., 2022), while high-dose corticosterone was administered to mice in two studies (Chou et al., 2022; Yu et al., 2022). Other models included the use of lipopolysaccharide (Yao et al., 2015), chronic social defeat stress (Li H. et al., 2021), maternal separation (Mi et al., 2022), ethanol binge drinking (Nascimento et al., 2020) and streptozotocin to model diabetes-induced depression (Huang et al., 2016). To determine that a depressive-like state had been induced by the animal models, which could then be reversed by compounds with antidepressant activity, behavior was predominantly assessed with three main tests, which included the forced swim test (FST) (19 studies), tail suspension test (TST) (13 studies) and sucrose preference test (SPT) (16 studies)—multiple studies used two or more of these tasks. One study assessed behavior in the splash test as well as nest building (Mi et al., 2022), while one study measured locomotor activity and neuromuscular endurance (Singh et al., 2014). Twenty one of the 50 studies did not use an animal model of depression per se, and tested antidepressant activity solely with standalone antidepressant screens. This included 18 studies which used the FST and 10 that used the TST (seven studies used both); only two of these 21 studies used rats (Matsuzaki et al., 2013; Rakoczy et al., 2023).

Antidepressant effects of mushroom extracts

The Kingdom Fungi encompasses many known species which can be further classified into subgroups by the mechanism with which they reproduce and disseminate their spores (Boundless, 2024). Fungi subcategories include mushrooms, as well as other fungi such as moulds and yeasts. Mushrooms from the genus Psilocybe are of particular interest as many from the genus are known to contain the psychoactive compounds psilocybin and psilocin. This includes the species Psilocybe cubensis, which has been demonstrated to be able to alleviate depression and anxiety symptoms in clinical trials (Ross et al., 2016; Goodwin et al., 2022). Other mushrooms species such as H. erinaceus and G. lucidum do not necessarily contain psychoactive compounds, but are still of interest in models and studies of depression. Most research investigating the use of medicinal mushrooms and their extracts to treat depression has been in preclinical settings, rather than in clinical trials.

Of the 19 species of mushroom tested for antidepressant-like activity in the current review, the most common one was G. lucidum, in nine studies Table 1. Two studies used UCMS and reported 28-day treatment with doses of 100–500 mg/kg, p.o. exerted antidepressant-like effects in the SPT (Cheng, 2023) and both the SPT and FST (Zhao et al., 2021). A 5 mg/kg, i.p. dose in mice exerted antidepressant-like effects in the TST and FST after chronic social defeat stress (Li H. et al., 2021), while effects in mice subjected to the maternal separation model were reversed with a 21-day treatment with 40 mg/kg, i.p. of extract (Mi et al., 2022); 100 mg/kg, p.o. also reversed immobility in the FST in a binge-alcohol model (Nascimento et al., 2020). Antidepressant screens found positive effects with chronic doses of 100–1,000 mg/kg, p.o. in the FST and TST (Matsuzaki et al., 2013; Socala et al., 2015; Singh et al., 2021; Ezurike et al., 2023). Significant antidepressant-like effects were observed with the UCMS model with Ganoderma sp. extracts (21-day, 20–30 mg/kg, i.v.) (Zhang L. et al., 2021); in this study, the authors did not specify with species of Ganoderma the active compound ganoderic acid-a was extracted from.

Hericium erinaceus was examined in seven studies. Extracts (25 mg/kg, i.p. and 200–400 mg/kg, p.o.) for 28 days reversed the effects of chronic restraint stress in the SPT, TST (Chong et al., 2021) and FST (Chiu et al., 2018). Doses of 12–24 mg (combined with Chlorella Vulgaris), p.o. for 21 days significantly reversed immobility in the FST caused by treatment with high dose corticosterone (Chou et al., 2022). A single oral dose of 200 mg/kg reversed increased immobility in the FST and TST caused by lipopolysaccharide (Yao et al., 2015), while 28-day administration at 20–60 mg/kg, p.o. decreased immobility in the TST and FST (Ryu et al., 2018).

For other mushroom species examined, effects were observed with the UCMS model with Marasmius androsaceus (28-day, 30–150 mg/kg, p.o.), Poria cocos (35-day, 100–300 mg/kg, p.o.) (Huang et al., 2020), Armillaria mellea (35-day, 250–1,000 mg/kg, p.o.) (Lin et al., 2021a), Agaricus brasiliensis (30-day, 3,000 mg/kg, p.o.) (Xin et al., 2022) and Xylaria sp. (28-day, 500–2000 mg/kg, i.g.) (Tan et al., 2016). Other animal models included antidepressant-like effects in a model of menopausal depression (Pleurotus eryngii, 79-day, 500 mg/kg, p.o.) (Minami et al., 2013), chronic restraint stress (Pleurotus citrinopileatus, 14-day, 1,200 mg/kg, in food) (Nakamichi et al., 2016) (M. androsaceus, 14-day, i.g.) (Zhao et al., 2023) and high-dose corticosterone (P-coumaric acid–compound found in some mushrooms, 3-day, 75 mg/kg, i.p.) (Yu et al., 2022).

As an antidepressant screen, studies using the standalone FST and TST reported significant antidepressant-like effects with Ganoderma applanatum, Ganoderma philippii, and Ganoderma brownii (single dose, 100–400 mg/kg, p.o.) (Singh et al., 2021), Grifola frondosa (1/5-days, in a 1:1-1:4 ratio of Griflola frondosa powder to rat chow ratio) while Pleurotus ostreatus had no effect in the same study (Bao et al., 2017), P. cubensis (single dose. 1,000 mg/kg, p.o. (Hernandez-Leon et al., 2024), and single dose 10–40 mg/kg, i.p., combined with ketamine) (Mahmoudi et al., 2018), P. eryngii (single dose, 20 mg/kg, i.p.) (Park et al., 2021), M. androsaceus (7-day, 50–250 mg/kg, p.o.) (Song et al., 2016; Song et al., 2020), Lentinula edodes (single dose 10 ml/kg p.o., [30% water soluble chitosan, 30% Allium sativum extract, 30% L. edodes extract, 0.5% Dioscorea Batatas extract, 0.5% bamboo salt extract]) (Koo et al., 2008), A. mellea (single dose, 5–20 mg/kg, i.p.) (Zhang T. et al., 2021), as well as ergosterol and derivatives (single dose, 0.1–20 mg/kg, i.p.) (Lin et al., 2017), and the mushroom extracts psilocybin and norbaeocystin (three doses over 24 h, 1 mg/kg, i.g.) (Rakoczy et al., 2023). No antidepressant effect was observed for Collybolide (a fungal metabolite; 2 mg/kg, i.p.) extract (Gupta et al., 2016).

 Antidepressant effects of fungus extracts

For the seven species of fungus that do not produce mushrooms, antidepressant activity was examined using the UCMS model in six studies Table 2. Antidepressant-like effects on the SPT and/or FST were observed with Cordyceps militaris (34-day, 125–500 mg/kg, p.o.) (Lin et al., 2021b) and (42-day, 20–40 mg/kg, i.g.) (Tianzhu et al., 2014), Paecilomyces tenuipes (28-day, 40–1,000 mg/kg, p.o.) (Liu C. et al., 2017) and (21-day, 40–2,500 mg/kg, p.o.) (Li et al., 2019), Paecilomyces hepiali (28-day, 80–2000 mg/kg, p.o.) (Wang et al., 2017) and Beauveria sp. (21-day, 25–100 mg/kg, i.g.) (Zhou et al., 2005). Treatment with Ophiocordyceps formosana (28-day, 2.5 mg, p.o.) reversed TST deficits in a streptozotocin-induced model of diabetic depression (Huang et al., 2016). Three studies used standalone animal antidepressant screens, in which Cordyceps sinensis decreased immobility in the TST (5-day, 5–10 ml/kg, p.o.) (Nishizawa et al., 2007) and locomotor activity (30-day, 300–500 mg/kg, p.o.) (Singh et al., 2014), while a wide range of Penicillium sp. derivatives (single dose, 30 mg/kg, i.p.) were active in the FST (Jin et al., 2019).

 Discussion

In the current analysis, we have summarized the main findings from a scoping review of the effects of mushroom and fungus extracts in preclinical tests of antidepressant efficacy. While this topic covers a broad range of compounds and techniques, several important themes are evident. Firstly, a large number of different species exhibit antidepressant-like activity, including 19 species of mushrooms and seven species of other fungi. For each of these, there can be multiple derivatives with their own antidepressant-like effects; for example, one study with Penicillium sp. identified 28 individual compounds with antidepressant-like effects in the FST (Jin et al., 2019), including some with more potent effects than the positive control fluoxetine. Thus, it appears that there is significant potential for novel compounds with antidepressant activity within these organisms. While this includes mushrooms with extracts that have traditionally been associated with psychoactive properties, such as P. cubensis, other novel compounds were identified with antidepressant-like effects. For example, P-coumaric acid was found to exhibit antidepressant-like effects after high dose corticosterone treatment (Yu et al., 2022); and was previously reported to exert pro-cognitive and anxiolytic effects in rodents (Scheepens et al., 2014; Kim et al., 2017; Ghaderi et al., 2022). Several of the species evaluated in this review have been tested in humans, confirming benefits for clinical depression. The antidepressant effects of psilocybin and psilocin, which are present in multiple of the current mushroom species are now well established (Griffiths et al., 2016; Ross et al., 2016; Davis et al., 2021; Eisenstein, 2022; Goodwin et al., 2022). In addition, one study showed that menopausal women experienced a reduction in depression and anxiety after 4 weeks of Hericium erinaceus intake (Nagano et al., 2010) while another showed a non-significant trend of reduced depression in women with fibromyalgia who received micromilled G. lucidum carpophores for 6 weeks (Pazzi et al., 2020).

Secondly, viewed as a whole, there are a number of both strengths and limitations within this literature. A positive is that the majority of studies administered compounds orally. While for many, use of oral gavage on a daily basis is technically more challenging than i.p. or s.c. drug administration in rodents (Turner et al., 2011), it strongly increases the translational validity of the studies, as human trials will be likely to use the same route of administration and be affected by similar pharmacokinetic processes, such as first-pass metabolism and low bioavailability (Bicker et al., 2020). It is also promising that antidepressant-like effects were observed across a wide duration of treatments with psychedelic and non-psychedelic-containing mushrooms and other fungi. Psychedelic compounds generally induce rapid drug tolerance upon repeated administration (Baumeister et al., 2014; Huang et al., 2022), where 5-HT2A receptor desensitization and/or downregulation leads to functional tolerance that can last several days (Buchborn et al., 2015; de la Fuente Revenga et al., 2022). However, observations of antidepressant-like effects weeks after treatment indicate that therapeutic effects may be sustained with these compounds (Aleksandrova and Phillips, 2021; Kelmendi et al., 2022). Various psychedelics have been reported to enhance neuroplasticity (synapto- and dendritogenesis) in frontocorticolimbic circuitry and increase functional connectivity in the brain, presumably reversing structural and functional deficits in depression (Aleksandrova and Phillips, 2021; Kelmendi et al., 2022). These psychedelic-induced structural and functional changes have been shown to last for weeks to months in animal models and/or humans and are thought to underlie the sustained therapeutic efficacy of these compounds (Aleksandrova and Phillips, 2021; Kelmendi et al., 2022).

While not necessarily a weakness, an extremely wide range of doses of extracts were tested in the current studies. From Tables 1, 2, these range from 1 mg/kg (Li H. et al., 2021; Rakoczy et al., 2023) to 3,000 mg/kg (Xin et al., 2022). Part of this reflects the effects of different routes of administration. Most of the extracts were administered orally, which is associated with a need for higher dosing, and therefore many of these studies included doses in the hundreds of milligrams per kilogram. But this wide range of dosing also represents the likelihood that many of the extracts were in early stage development, where the active compounds are unknown, and so whole product, heterogeneous extracts are used where the efficacy of active compounds may be modified through both pharmacodynamic (e.g., receptor antagonism) and pharmacokinetic (e.g., absorption) processes by many inactive compounds. Thus, such studies are early-stage screens as part of an iterative process (Reis et al., 2017), and in the case of positive effects in the antidepressant screen, this will lead to refinement of extracts by further chemical analysis and result in greater potency, with a lower dose needed.

Multiple different animal models of depression and antidepressant screens were used to test for antidepressant-like effects. Although there is no universally accepted definition, animal models of depression are typically more complex and chronic than antidepressant screens, and are used to emulate some feature(s) of depression, such as its symptoms (face validity) or underlying biology (construct validity) (Geyer et al., 1995; Willner, 1984; Belzung and Lemoine, 2011; van den Berg, 2022). By contrast, antidepressant screens such as the TST and FST are acute and were originally designed to identify novel antidepressant compounds (predictive validity) without regard for similarity to the human condition (Commons et al., 2017). The most commonly used animal model of depression in the present studies was the UCMS paradigm, which is based on the development of anhedonia following exposure to chronic, variable stressors (Willner, 2017; Nollet, 2021). The model has strong theoretical appeal, based on the chronic onset of the antidepressant response, and performs well on key measures of validity (Willner, 1997). Nevertheless, the model has been criticized on both theoretical and practical grounds (Forbes et al., 1996; Barr and Phillips, 1998; Planchez et al., 2019; Markov and Novosadova, 2022), although a recent meta-analysis supported the utility of the model when specifically measuring anhedonia (Antoniuk et al., 2019). Thus, greater confidence should be placed in those studies with mushroom and fungus extracts that measured anhedonia (such as with the SPT) than those that did not. Alternate models of depression were also conducted, such as chronic social defeat stress (Li H. et al., 2021) and maternal separation (Mi et al., 2022), but typically only in a single study; given the importance of reproducibility within this field (Petković and Chaudhury, 2022), the literature will benefit from similar findings from alternate groups, or reproduction by the same groups themselves. Additionally, there are a number of other well-established and commonly used animal models of depression that should be used to assess antidepressant activity with these extracts, including surgical, pharmacological and genetic models (Barr and Phillips, 2002; Song and Leonard, 2005; Barr et al., 2011; Overstreet, 2012; Overstreet and Wegener, 2013; Vollmayr and Gass, 2013; Hendriksen et al., 2015; Czéh et al., 2016; Aleksandrova et al., 2019).

Slightly under half of the studies (22) utilized antidepressant screens such as the FST and TST, rather than models of depression. In most cases, these studies were methodologically sound, and used the appropriate controls, such as concurrent testing for locomotor activity and positive drug controls (Bogdanova et al., 2013; Yankelevitch-Yahav et al., 2015). However, several studies utilized variants of the FST, such as the “weight-loaded” FST (Xu, 2016; Liu Y. et al., 2017), whose validity is less well determined, while one study ascribed antidepressant-like effects based on changes in locomotor activity (Singh et al., 2014), which is a behavior with low specificity for depression. An additional concern was the small proportion of female animals tested, given that major depression is twice as common in women as in men: this issue is prevalent in the field of animal models of neuropsychiatric disorders as a whole (Kokras and Dalla, 2014), but future studies in this area should consider including female animals (Gobinath et al., 2018). Overall, however, the present review suggests that there is significant potential for novel antidepressant drug development with mushroom and fungus extracts provided that models and screens are conducted with high integrity.

 Author contributions

CW: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing–original draft, Writing–review and editing. GK: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing–original draft, Writing–review and editing. LA: Formal Analysis, Writing–original draft, Writing–review and editing. WP: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Writing–original draft, Writing–review and editing. AB: Conceptualization, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing–original draft, Writing–review and editing.

 Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. AB was supported by a grant from NSERC. CW and GK were supported by BioTalent Canada with financial support from Translational Life Sciences.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1387158/full#supplementary-material

References Aleksandrova L. R. Phillips A. G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol. Sci. 42 (11), 929–942. Epub 2021/09/28. 10.1016/j.tips.2021.08.003 Aleksandrova L. R. Wang Y. T. Phillips A. G. (2019). Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response. Neurosci. Biobehav Rev. 105, 1–23. Epub 2019/07/25. 10.1016/j.neubiorev.2019.07.007 Alo R. Zizza M. Fazzari G. Facciolo R. M. Canonaco M. (2019). Genistein modifies hamster behavior and expression of inflammatory factors following subchronic unpredictable mild stress. Neuroendocrinology 108 (2), 98–108. 10.1159/000495209 Antoniuk S. Bijata M. Ponimaskin E. Wlodarczyk J. (2019). Chronic unpredictable mild stress for modeling depression in rodents: meta-analysis of model reliability. Neurosci. Biobehav Rev. 99, 101–116. Epub 2018/12/12. 10.1016/j.neubiorev.2018.12.002 Anuar A. M. Minami A. Matsushita H. Ogino K. Fujita K. Nakao H. (2022). Ameliorating effect of the edible mushroom Hericium erinaceus on depressive-like behavior in ovariectomized rats. Biol. Pharm. Bull. 45 (10), 1438–1443. Epub 2022/10/03. 10.1248/bpb.b22-00151 Bao H. Ran P. Sun L. Hu W. Li H. Xiao C. (2017). Griflola frondosa (GF) produces significant antidepressant effects involving AMPA receptor activation in mice. Pharm. Biol. 55 (1), 299–305. Epub 2016/12/13. 10.1080/13880209.2016.1235590 Barr A. M. Boyda H. N. Procyshyn R. M. (2011). “Withdrawal,” in Animal models of drug addiction. Editor Olmstead M. C. (Totowa, NJ: Humana Press), 431–459. Barr A. M. Phillips A. G. (1998). Chronic mild stress has no effect on responding by rats for sucrose under a progressive ratio schedule. Physiol. Behav. 64 (5), 591–597. PubMed PMID: 9817568. 10.1016/s0031-9384(98)00060-2 Barr A. M. Phillips A. G. (2002). Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of D-amphetamine. Pharmacol. Biochem. Behav. 71 (1-2), 293–299. PubMed PMID: 11812535. 10.1016/s0091-3057(01)00664-5 Barr A. M. Powell S. B. Markou A. Geyer M. A. (2006). Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51 (3), 457–465. PubMed PMID: 16762376. 10.1016/j.neuropharm.2006.04.004 Baumeister D. Barnes G. Giaroli G. Tracy D. (2014). Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther. Adv. Psychopharmacol. 4 (4), 156–169. Epub 2014/08/02. 10.1177/2045125314527985 Belzung C. Lemoine M. (2011). Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. mood anxiety Disord. 1 (1), 9. Epub 2011/01/01. 10.1186/2045-5380-1-9 Bicker J. Fortuna A. Alves G. Falcão A. (2020). Nose-to-brain delivery of natural compounds for the treatment of central nervous system disorders. Curr. Pharm. Des. 26 (5), 594–619. Epub 2020/01/16. 10.2174/1381612826666200115101544 Bogdanova O. V. Kanekar S. D'Anci K. E. Renshaw P. F. (2013). Factors influencing behavior in the forced swim test. Physiol. Behav. 118, 227–239. Epub 2013/05/21. 10.1016/j.physbeh.2013.05.012 Boundless (2024) Fungi reproduction: UC Davis office of the provost. Available at: https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/Book%3A_General_Biology_(Boundless)/24%3A_Fungi/24.01%3A_Characteristics_of_Fungi/24.1C%3A_Fungi_Reproduction (updated 4/18/2024). Boyda H. N. Procyshyn R. M. Pang C. C. Hawkes E. Wong D. Jin C. H. (2013). Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One 8 (1), e53459. PubMed PMID: 23326434. 10.1371/journal.pone.0053459 Boyda H. N. Procyshyn R. M. Tse L. Yuen J. W. Y. Honer W. G. Barr A. M. (2021). A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLoS One 16 (1), e0246211. Epub 2021/01/29. 10.1371/journal.pone.0246211 Boyda H. N. Ramos-Miguel A. Procyshyn R. M. Topfer E. Lant N. Choy H. H. (2014). Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int. J. Neuropsychopharmacol. 17 (1), 77–90. PubMed PMID: 23953063. 10.1017/S1461145713000795 Braun D. Rosenberg A. M. Rabaniam E. Haruvi R. Malamud D. Barbara R. (2024). High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin. Mol. Psychiatry. Epub 2024/01/18. 10.1038/s41380-023-02391-7 Buchborn T. Schröder H. Dieterich D. C. Grecksch G. Höllt V. (2015). Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites. Behav. Brain Res. 281, 62–68. Epub 2014/12/17. 10.1016/j.bbr.2014.12.014 Carhart-Harris R. L. Bolstridge M. Rucker J. Day C. M. Erritzoe D. Kaelen M. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3 (7), 619–627. Epub 2016/05/24. 10.1016/s2215-0366(16)30065-7 Cheng H. Y. (2023). Ganoderma lucidum ameliorated depression-like behavior in an unpredictable chronic mild stress rat model via regulation of monoamines. Res. Square. 10.21203/rs.3.rs-2389771/v1 Available at: https://www.researchsquare.com/article/rs-2389771/v1. Chiu C. H. Chyau C. C. Chen C. C. Lee L. Y. Chen W. P. Liu J. L. (2018). Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice. Int. J. Mol. Sci. 19 (2), 341. Epub 2018/01/25. 10.3390/ijms19020341 Chong P. S. Poon C. H. Roy J. Tsui K. C. Lew S. Y. Phang M. W. L. (2021). Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression. Chin. Med. 16 (1), 132. Epub 2021/12/09. 10.1186/s13020-021-00546-8 Chou M. Y. Ho J. H. Huang M. J. Chen Y. J. Yang M. D. Lin L. H. (2022). Potential antidepressant effects of a dietary supplement from the chlorella and lion's mane mushroom complex in aged SAMP8 mice. Front. Nutr. 9, 977287. Epub 2022/09/20. 10.3389/fnut.2022.977287 Collaborators G. M. D. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9 (2), 137–150. Epub 2022/01/14. 10.1016/s2215-0366(21)00395-3 Commons K. G. Cholanians A. B. Babb J. A. Ehlinger D. G. (2017). The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem. Neurosci. 8 (5), 955–960. Epub 2017/03/14. 10.1021/acschemneuro.7b00042 Czéh B. Fuchs E. Wiborg O. Simon M. (2016). Animal models of major depression and their clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 293–310. Epub 2015/04/22. 10.1016/j.pnpbp.2015.04.004 Davis A. K. Barrett F. S. May D. G. Cosimano M. P. Sepeda N. D. Johnson M. W. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry 78 (5), 481–489. Epub 2020/11/05. 10.1001/jamapsychiatry.2020.3285 de la Fuente Revenga M. Jaster A. M. McGinn J. Silva G. Saha S. González-Maeso J. (2022). Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT(2A) receptor agonists in mice. ACS Chem. Neurosci. 13 (16), 2436–2448. Epub 2022/07/29. 10.1021/acschemneuro.2c00170 Eisenstein M. (2022). The psychedelic escape from depression. Nature 609 (7929), S87–S89. Epub 2022/09/29. 10.1038/d41586-022-02872-9 Ezurike P. U. Odunola E. Oke T. A. Bakre A. G. Olumide O. Odetoye O. (2023). Ganoderma lucidum ethanol extract promotes weight loss and improves depressive-like behaviors in male and female Swiss mice. Physiol. Behav. 265, 114155. Epub 2023/03/13. 10.1016/j.physbeh.2023.114155 Fijałkowska A. Jędrejko K. Sułkowska-Ziaja K. Ziaja M. Kała K. Muszyńska B. (2022). Edible mushrooms as a potential component of dietary interventions for major depressive disorder. Foods (Basel, Switz.) 11 (10), 1489. Epub 2022/05/29. 10.3390/foods11101489 Forbes N. F. Stewart C. A. Matthews K. Reid I. C. (1996). Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol. Behav. 60 (6), 1481–1484. Epub 1996/12/01. 10.1016/s0031-9384(96)00305-8 Friedrich M. J. (2017). Depression is the leading cause of disability around the world. Jama 317 (15), 1517. Epub 2017/04/19. 10.1001/jama.2017.3826 Geyer M. A. Markou A. (1995). “Animal models of psychiatric disorders,” in Psychopharmacology: the fourth generation of progress. Psychopharmacology: the fourth generation of progress. Editors Bloom F. E. Kupfer D. J. (New York: Raven Press), 787–798. Ghaderi S. Gholipour P. Komaki A. Salehi I. Rashidi K. Esmaeil Khoshnam S. (2022). p-Coumaric acid ameliorates cognitive and non-cognitive disturbances in a rat model of Alzheimer's disease: the role of oxidative stress and inflammation. Int. Immunopharmacol. 112, 109295. Epub 2022/10/05. 10.1016/j.intimp.2022.109295 Gobinath A. R. Wong S. Chow C. Lieblich S. E. Barr A. M. Galea L. A. M. (2018). Maternal exercise increases but concurrent maternal fluoxetine prevents the increase in hippocampal neurogenesis of adult offspring. Psychoneuroendocrinology 91, 186–197. Epub 2018/03/27. 10.1016/j.psyneuen.2018.02.027 Goodwin G. M. Aaronson S. T. Alvarez O. Arden P. C. Baker A. Bennett J. C. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387 (18), 1637–1648. Epub 2022/11/03. 10.1056/NEJMoa2206443 Gravina A. G. Pellegrino R. Auletta S. Palladino G. Brandimarte G. D'Onofrio R. (2023). Hericium erinaceus, a medicinal fungus with a centuries-old history: evidence in gastrointestinal diseases. World J. gastroenterology 29 (20), 3048–3065. Epub 2023/06/22. 10.3748/wjg.v29.i20.3048 Griffiths R. R. Johnson M. W. Carducci M. A. Umbricht A. Richards W. A. Richards B. D. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30 (12), 1181–1197. Epub 2016/12/03. 10.1177/0269881116675513 Gupta A. Gomes I. Bobeck E. N. Fakira A. K. Massaro N. P. Sharma I. (2016). Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity. Proc. Natl. Acad. Sci. U. S. A. 113 (21), 6041–6046. Epub 2016/05/11. 10.1073/pnas.1521825113 Haikazian S. Chen-Li D. C. J. Johnson D. E. Fancy F. Levinta A. Husain M. I. (2023). Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res. 329, 115531. Epub 2023/10/16. 10.1016/j.psychres.2023.115531 Hendriksen H. Korte S. M. Olivier B. Oosting R. S. (2015). The olfactory bulbectomy model in mice and rat: one story or two tails? Eur. J. Pharmacol. 753, 105–113. Epub 2014/12/03. 10.1016/j.ejphar.2014.10.033 Hernandez-Leon A. Escamilla-Orozco R. I. Tabal-Robles A. R. Martínez-Vargas D. Romero-Bautista L. Escamilla-Soto G. (2024). Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. J. Ethnopharmacol. 320, 117415. Epub 2023/11/18. 10.1016/j.jep.2023.117415 Higgins J. P. T. Green S. (2011) Cochrane Handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons. Hill M. N. Barr A. M. Ho W. S. Carrier E. J. Gorzalka B. B. Hillard C. J. (2007). Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J. Neurochem. 103 (1), 47–56. Epub 2007/06/15. 10.1111/j.1471-4159.2007.04688.x Hosanagar A. Cusimano J. Radhakrishnan R. (2021). Therapeutic potential of psychedelics in the treatment of psychiatric disorders, Part 1: psychopharmacology and neurobiological effects. J. Clin. Psychiatry 82 (2), 20ac13786. Epub 2021/05/15. 10.4088/JCP.20ac13786 Hossen S. M. M. Islam M. J. Hossain M. R. Barua A. Uddin M. G. Emon N. U. (2021). CNS anti-depressant, anxiolytic and analgesic effects of Ganoderma applanatum (mushroom) along with ligand-receptor binding screening provide new insights: multi-disciplinary approaches. Biochem. biophysics Rep. 27, 101062. Epub 2021/07/22. 10.1016/j.bbrep.2021.101062 Huang C. W. Hong T. W. Wang Y. J. Chen K. C. Pei J. C. Chuang T. Y. (2016). Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse model. BMC Complement. Altern. Med. 16 (1), 310. Epub 2016/08/25. 10.1186/s12906-016-1278-7 Huang J. Pham M. Panenka W. J. Honer W. G. Barr A. M. (2022). Chronic treatment with psilocybin decreases changes in body weight in a rodent model of obesity. Front. Psychiatry 13, 891512. Epub 2022/06/07. 10.3389/fpsyt.2022.891512 Huang Y. J. Hsu N. Y. Lu K. H. Lin Y. E. Lin S. H. Lu Y. S. (2020). Poria cocos water extract ameliorates the behavioral deficits induced by unpredictable chronic mild stress in rats by down-regulating inflammation. J. Ethnopharmacol. 258, 112566. Epub 2020/01/14. 10.1016/j.jep.2020.112566 Hung C. I. (2014). Factors predicting adherence to antidepressant treatment. Curr. Opin. Psychiatry 27 (5), 344–349. Epub 2014/07/18. 10.1097/yco.0000000000000086 Jin Q. Fu Z. Guan L. Jiang H. (2019). Syntheses of benzo[d]Thiazol-2(3H)-One derivatives and their antidepressant and anticonvulsant effects. Mar. drugs 17 (7), 430. Epub 2019/07/26. 10.3390/md17070430 Kamal S. Jha M. K. Radhakrishnan R. (2023). Role of psychedelics in treatment-resistant depression. Psychiatr. Clin. North Am. 46 (2), 291–305. Epub 2023/05/07. 10.1016/j.psc.2023.02.004 Kelmendi B. Kaye A. P. Pittenger C. Kwan A. C. (2022). Psychedelics. Curr. Biol. 32 (2), R63–R67. Epub 2022/01/26. 10.1016/j.cub.2021.12.009 Kim H. B. Lee S. Hwang E. S. Maeng S. Park J. H. (2017). p-Coumaric acid enhances long-term potentiation and recovers scopolamine-induced learning and memory impairments. Biochem. Biophys. Res. Commun. 492 (3), 493–499. Epub 2017/08/24. 10.1016/j.bbrc.2017.08.068 Kokras N. Dalla C. (2014). Sex differences in animal models of psychiatric disorders. Br. J. Pharmacol. 171 (20), 4595–4619. Epub 2014/04/05. 10.1111/bph.12710 Koo H. N. Um J. Y. Kim H. M. Lee E. H. Sung H. J. Kim I. K. (2008). Effect of pilopool on forced swimming test in mice. Int. J. Neurosci. 118 (3), 365–374. Epub 2008/02/27. 10.1080/00207450701593145 Kramer M. S. Cutler N. Feighner J. Shrivastava R. Carman J. Sramek J. J. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281 (5383), 1640–1645. PubMed PMID: 9733503. 10.1126/science.281.5383.1640 Li H. Xiao Y. Han L. Jia Y. Luo S. Zhang D. (2021a). Ganoderma lucidum polysaccharides ameliorated depression-like behaviors in the chronic social defeat stress depression model via modulation of Dectin-1 and the innate immune system. Brain Res. Bull. 171, 16–24. Epub 2021/03/12. 10.1016/j.brainresbull.2021.03.002 Li T. J. Lee T. Y. Lo Y. Lee L. Y. Li I. C. Chen C. C. (2021b). Hericium erinaceus mycelium ameliorate anxiety induced by continuous sleep disturbance in vivo . BMC complementary Med. Ther. 21 (1), 295. Epub 2021/12/07. 10.1186/s12906-021-03463-3 Li Y. Han L. Lu T. Noman M. Qiang W. Lan X. (2019). Antidepressant-like activities of extracts of the fungus Paecilomyces tenuipes M98. Psychiatry Clin. Psychopharmacol. 29 (4), 872–879. 10.1080/24750573.2019.1691352 Lian L. Kim D. D. Procyshyn R. M. Cázares D. Honer W. G. Barr A. M. (2022). Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS One 17 (4), e0267808. Epub 2022/04/30. 10.1371/journal.pone.0267808 Lin M. Li H. Zhao Y. Cai E. Zhu H. Gao Y. (2017). Ergosteryl 2-naphthoate, an ergosterol derivative, exhibits antidepressant effects mediated by the modification of GABAergic and glutamatergic systems. Mol. (Basel, Switz.) 22 (4), 565. Epub 2017/04/01. 10.3390/molecules22040565 Lin Y. E. Chen Y. C. Lu K. H. Huang Y. J. Panyod S. Liu W. T. (2021b). Antidepressant-like effects of water extract of Cordyceps militaris (Linn.) Link by modulation of ROCK2/PTEN/Akt signaling in an unpredictable chronic mild stress-induced animal model. J. Ethnopharmacol. 276, 114194. Epub 2021/05/12. 10.1016/j.jep.2021.114194 Lin Y. E. Wang H. L. Lu K. H. Huang Y. J. Panyod S. Liu W. T. (2021a). Water extract of Armillaria mellea (Vahl) P. Kumm. Alleviates the depression-like behaviors in acute- and chronic mild stress-induced rodent models via anti-inflammatory action. J. Ethnopharmacol. 265, 113395. Epub 2020/09/22. 10.1016/j.jep.2020.113395 Liu C. Wang J. Xu S. An S. Tang S. He J. (2017a). Paecilomyces tenuipes extract prevents depression-like behaviors in chronic unpredictable mild stress-induced rat model via modulation of neurotransmitters. Mol. Med. Rep. 16 (2), 2172–2178. Epub 2017/06/29. 10.3892/mmr.2017.6807 Liu Y. Li L. An S. Zhang Y. Feng S. Zhao L. (2017b). Antifatigue effects of antrodia cinnamomea cultured mycelium via modulation of oxidative stress signaling in a mouse model. Biomed. Res. Int. 2017, 9374026. Epub 2017/04/21. 10.1155/2017/9374026 Lu X. Barr A. M. Bartfai T. (2005). Galanin receptors as novel drug targets for the treatment of depression and anxiety. Drug Dev. Res. 65 (4), 227–236. 10.1002/ddr.20026 Mahmoudi E. Faizi M. Hajiaghaee R. Razmi A. (2018). Alteration of depressive-like behaviors by Psilocybe cubensis alkaloid extract in mice: the role of glutamate pathway. Res. J. Pharmacogn. 5 (2), 17–24. 10.22127/rjp.2018.58486 Markov D. D. Novosadova E. V. (2022). Chronic unpredictable mild stress model of depression: possible sources of poor reproducibility and latent variables. Biology 11 (11), 1621. Epub 2022/11/12. 10.3390/biology11111621 Matsuzaki H. Shimizu Y. Iwata N. Kamiuchi S. Suzuki F. Iizuka H. (2013). Antidepressant-like effects of a water-soluble extract from the culture medium of Ganoderma lucidum mycelia in rats. BMC Complement. Altern. Med. 13, 370. Epub 2013/12/29. 10.1186/1472-6882-13-370 McLachlan G. (2018). Treatment resistant depression: what are the options? Bmj 363, k5354. Epub 2018/12/20. 10.1136/bmj.k5354 Mi X. Zeng G. R. Liu J. Q. Luo Z. S. Zhang L. Dai X. M. (2022). Ganoderma lucidum triterpenoids improve maternal separation-induced anxiety- and depression-like behaviors in mice by mitigating inflammation in the periphery and brain. Nutrients 14 (11), 2268. Epub 2022/06/11. 10.3390/nu14112268 Minami A. Matsushita H. Horii Y. Ieno D. Matsuda Y. Saito M. (2013). Improvement of depression-like behavior and memory impairment with the ethanol extract of Pleurotus eryngii in ovariectomized rats. Biol. Pharm. Bull. 36 (12), 1990–1995. Epub 2013/12/03. 10.1248/bpb.b13-00657 Moussa A. Y. Fayez S. Xiao H. Xu B. (2022). New insights into antimicrobial and antibiofilm effects of edible mushrooms. Food Res. Int. Ott.( Ont) 162 (Pt A), 111982. Epub 2022/12/04. 10.1016/j.foodres.2022.111982 Nagano M. Shimizu K. Kondo R. Hayashi C. Sato D. Kitagawa K. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed. Res. (Tokyo, Jpn.) 31 (4), 231–237. Epub 2010/09/14. 10.2220/biomedres.31.231 Nakamichi N. Nakayama K. Ishimoto T. Masuo Y. Wakayama T. Sekiguchi H. (2016). Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. Brain Behav. 6 (6), e00477. Epub 2016/05/03. 10.1002/brb3.477 Nascimento C. P. Luz D. A. da Silva C. C. S. Malcher C. M. R. Fernandes L. M. P. Dalla Santa H. S. (2020). Ganoderma lucidum ameliorates neurobehavioral changes and oxidative stress induced by ethanol binge drinking. Oxidative Med. Cell. Longev. 2020, 2497845. Epub 2020/08/18. 10.1155/2020/2497845 Nishizawa K. Torii K. Kawasaki A. Katada M. Ito M. Terashita K. (2007). Antidepressant-like effect of Cordyceps sinensis in the mouse tail suspension test. Biol. Pharm. Bull. 30 (9), 1758–1762. Epub 2007/09/11. 10.1248/bpb.30.1758 Nollet M. (2021). Models of depression: unpredictable chronic mild stress in mice. Curr. Protoc. 1 (8), e208. 10.1002/cpz1.208 Overstreet D. H. (2012). Modeling depression in animal models. Methods Mol. Biol. 829, 125–144. Epub 2012/01/11. 10.1007/978-1-61779-458-2_7 Overstreet D. H. Wegener G. (2013). The flinders sensitive line rat model of depression--25 years and still producing. Pharmacol. Rev. 65 (1), 143–155. Epub 2013/01/16. 10.1124/pr.111.005397 Palhano-Fontes F. Barreto D. Onias H. Andrade K. C. Novaes M. M. Pessoa J. A. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol. Med. 49 (4), 655–663. Epub 2018/06/16. 10.1017/s0033291718001356 Pandya U. Dhuldhaj U. Sahay N. S. (2019). Bioactive mushroom polysaccharides as antitumor: an overview. Nat. Prod. Res. 33 (18), 2668–2680. Epub 2018/05/05. 10.1080/14786419.2018.1466129 Park Y. S. Jang S. Lee H. Kang S. Seo H. Yeon S. (2021). Identification of the antidepressant function of the edible mushroom Pleurotus eryngii. J. fungi (Basel, Switz.) 7 (3), 190. Epub 2021/04/04. 10.3390/jof7030190 Pazzi F. Adsuar J. C. Domínguez-Muñoz F. J. García-Gordillo M. A. Gusi N. Collado-Mateo D. (2020). Ganoderma lucidum effects on mood and health-related quality of life in women with fibromyalgia. Healthc. (Basel, Switz.) 8 (4), 520. Epub 2020/12/04. 10.3390/healthcare8040520 Petković A. Chaudhury D. (2022). Encore: behavioural animal models of stress, depression and mood disorders. Front. Behav. Neurosci. 16, 931964. Epub 2022/08/26. 10.3389/fnbeh.2022.931964 Planchez B. Surget A. Belzung C. (2019). Animal models of major depression: drawbacks and challenges. J. neural Transm. (Vienna) 126 (11), 1383–1408. Epub 2019/10/05. 10.1007/s00702-019-02084-y Rakoczy R. J. Runge G. N. Sen A. K. Sandoval O. Nguyen Q. Roberts B. R. (2023). Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms. bioRxiv 2023. 10.1101/2023.10.19.563138 Reis F. S. Martins A. Vasconcelos M. H. Morales P. Ferreira ICFR (2017). Functional foods based on extracts or compounds derived from mushrooms. Trends Food Sci. Technol. 66, 48–62. 10.1016/j.tifs.2017.05.010 Ross S. Bossis A. Guss J. Agin-Liebes G. Malone T. Cohen B. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30 (12), 1165–1180. Epub 2016/12/03. 10.1177/0269881116675512 Rossom R. C. Shortreed S. Coleman K. J. Beck A. Waitzfelder B. E. Stewart C. (2016). Antidepressant adherence across diverse populations and healthcare settings. Depress Anxiety 33 (8), 765–774. Epub 2016/06/21. 10.1002/da.22532 Ryu S. Kim H. G. Kim J. Y. Kim S. Y. Cho K. O. (2018). Hericium erinaceus extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain. J. Med. food 21 (2), 174–180. Epub 2017/11/02. 10.1089/jmf.2017.4006 Scheepens A. Bisson J. F. Skinner M. (2014). p-Coumaric acid activates the GABA-A receptor in vitro and is orally anxiolytic in vivo . Phytotherapy Res. PTR 28 (2), 207–211. Epub 2013/03/28. 10.1002/ptr.4968 Sepúlveda-Lizcano L. Arenas-Villamizar V. V. Jaimes-Duarte E. B. García-Pacheco H. Paredes C. S. Bermúdez V. (2023). Metabolic adverse effects of psychotropic drug therapy: a systematic review. Eur. J. investigation health, Psychol. Educ. 13 (8), 1505–1520. Epub 2023/08/25. 10.3390/ejihpe13080110 Simonsson O. Carlbring P. Carhart-Harris R. Davis A. K. Nutt D. J. Griffiths R. R. (2023). Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis. Psychiatry Res. 327, 115349. Epub 2023/08/01. 10.1016/j.psychres.2023.115349 Singh K. P. Meena H. S. Negi P. S. (2014). Enhancement of neuromuscular activity by natural specimens and cultured mycelia of Cordyceps sinensis in mice. Indian J. Pharm. Sci. 76 (5), 458–461. 10.4103/0250-474X.143105 Singh R. Shri R. Singh A. P. Dhingra G. S. (2021). Valorization of Ganoderma species: chemical characterization and antidepressant-like activity. Waste Biomass Valorization 12 (4), 2025–2036. 10.1007/s12649-020-01157-4 Socala K. Nieoczym D. Grzywnowicz K. Stefaniuk D. Wlaz P. (2015). Evaluation of anticonvulsant, antidepressant-and anxiolytic-like effects of an aqueous extract from cultured mycelia of the lingzhi or reishi medicinal mushroom Ganoderma lucidum (higher basidiomycetes) in mice. Int. J. Med. mushrooms 17 (3), 209–218. Epub 2015/05/09. 10.1615/intjmedmushrooms.v17.i3.10 Song C. Leonard B. E. (2005). The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav Rev. 29 (4-5), 627–647. Epub 2005/06/01. 10.1016/j.neubiorev.2005.03.010 Song J. Geng X. Su Y. Zhang X. Tu L. Zheng Y. (2020). Structure feature and antidepressant-like activity of a novel exopolysaccharide isolated from Marasmius androsaceus fermentation broth. Int. J. Biol. Macromol. 165 (Pt B), 1646–1655. Epub 2020/10/12. 10.1016/j.ijbiomac.2020.10.015 Song J. Wang X. Huang Y. Qu Y. Teng L. Wang D. (2017). Antidepressant-like effects of Marasmius androsaceus metabolic exopolysaccharides on chronic unpredictable mild stress-induced rat model. Mol. Med. Rep. 16 (4), 5043–5049. Epub 2017/08/03. 10.3892/mmr.2017.7145 Song J. Xing G. Cao J. Teng L. Li C. Meng Q. (2016). Investigation of the antidepressant effects of exopolysaccharides obtained from Marasmius androsaceus fermentation in a mouse model. Mol. Med. Rep. 13 (1), 939–946. Epub 2015/12/10. 10.3892/mmr.2015.4584 Strauss D. Ghosh S. Murray Z. Gryzenhout M. (2022). An overview on the taxonomy, phylogenetics and ecology of the psychedelic genera Psilocybe, panaeolus, pluteus and gymnopilus. Front. For. Glob. Change 5. 10.3389/ffgc.2022.813998 Tan Y. F. Liao Z. L. Qiu Y. J. Zhu J. P. Yu E. Y. (2016). Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like effect of Wuling mycelia powder in rat. Biomed. Pharmacother. 78, 60–65. Epub 2016/02/24. 10.1016/j.biopha.2015.12.016 Teng T. Zhang Z. Yin B. Guo T. Wang X. Hu J. (2022). Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis. Transl. psychiatry 12 (1), 183. Epub 2022/05/05. 10.1038/s41398-022-01951-9 Tianzhu Z. Shihai Y. Juan D. (2014). Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress. Evidence-based complementary Altern. Med. eCAM. 2014, 438506. Epub 2015/01/15. 10.1155/2014/438506 Tse L. Procyshyn R. M. Fredrikson D. H. Boyda H. N. Honer W. G. Barr A. M. (2014). Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int. Clin. Psychopharmacol. 29 (3), 125–137. PubMed PMID: 24169026. 10.1097/YIC.0000000000000014 Turner P. V. Brabb T. Pekow C. Vasbinder M. A. (2011). Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Laboratory Animal Sci. JAALAS. 50 (5), 600–613. van den Berg H. (2022). Evaluating the validity of animal models of mental disorder: from modeling syndromes to modeling endophenotypes. Hist. Philosophy Life Sci. 44 (4), 59. 10.1007/s40656-022-00537-4 Venturella G. Ferraro V. Cirlincione F. Gargano M. L. (2021). Medicinal mushrooms: bioactive compounds, use, and clinical trials. Int. J. Mol. Sci. 22 (2), 634. Epub 2021/01/14. 10.3390/ijms22020634 Voineskos D. Daskalakis Z. J. Blumberger D. M. (2020). Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr. Dis. Treat. 16, 221–234. Epub 2020/02/06. 10.2147/ndt.s198774 Vollmayr B. Gass P. (2013). Learned helplessness: unique features and translational value of a cognitive depression model. Cell. tissue Res. 354 (1), 171–178. Epub 2013/06/14. 10.1007/s00441-013-1654-2 Wang J. Liu Y. Li L. Qi Y. Zhang Y. Li L. (2017). Dopamine and serotonin contribute to Paecilomyces hepiali against chronic unpredictable mild stress induced depressive behavior in Sprague Dawley rats. Mol. Med. Rep. 16 (4), 5675–5682. Epub 2017/08/30. 10.3892/mmr.2017.7261 Willner P. (1984). The validity of animal models of depression. Psychopharmacol. Berl. 83 (1), 1–16. Epub 1984/01/01. 10.1007/bf00427414 Willner P. (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacol. Berl. 134 (4), 319–329. Epub 1998/02/06. 10.1007/s002130050456 Willner P. (2017). The chronic mild stress (CMS) model of depression: history, evaluation and usage. Neurobiol. stress 6, 78–93. Epub 2017/02/24. 10.1016/j.ynstr.2016.08.002 Xin Y. Zhang Y. Zhang X. (2022). Antidepressant effect of water extract of royal sun medicinal mushroom, Agaricus brasiliensis (agaricomycetes), in mice exposed to chronic unpredictable mild stress. Int. J. Med. mushrooms 24 (4), 63–73. Epub 2022/06/14. 10.1615/IntJMedMushrooms.2022042726 Xu Y. F. (2016). Effect of polysaccharide from Cordyceps militaris (ascomycetes) on physical fatigue induced by forced swimming. Int. J. Med. mushrooms 18 (12), 1083–1092. Epub 2017/01/18. 10.1615/IntJMedMushrooms.v18.i12.30 Yadav D. Negi P. S. (2021). Bioactive components of mushrooms: processing effects and health benefits. Food Res. Int. Ott.( Ont) 148, 110599. Epub 2021/09/12. 10.1016/j.foodres.2021.110599 Yankelevitch-Yahav R. Franko M. Huly A. Doron R. (2015). The forced swim test as a model of depressive-like behavior. J. Vis. Exp. (97), 52587. Epub 2015/04/14. 10.3791/52587 Yao W. Zhang J. C. Dong C. Zhuang C. Hirota S. Inanaga K. (2015). Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 136, 7–12. Epub 2015/07/08. 10.1016/j.pbb.2015.06.012 Yu X. D. Zhang D. Xiao C. L. Zhou Y. Li X. Wang L. (2022). P-coumaric acid reverses depression-like behavior and memory deficit via inhibiting AGE-RAGE-mediated neuroinflammation. Cells 11 (10), 1594. Epub 2022/05/29. 10.3390/cells11101594 Yuen J. W. Y. Kim D. D. Procyshyn R. M. Panenka W. J. Honer W. G. Barr A. M. (2021). A focused review of the metabolic side-effects of clozapine. Front. Endocrinol. 12, 609240. Epub 2021/03/16. 10.3389/fendo.2021.609240 Zhang L. Zhang L. Sui R. (2021a). Ganoderic acid A-mediated modulation of microglial polarization is involved in depressive-like behaviors and neuroinflammation in a rat model of post-stroke depression. Neuropsychiatr. Dis. Treat. 17, 2671–2681. Epub 2021/08/24. 10.2147/ndt.s317207 Zhang T. Du Y. Liu X. Sun X. Cai E. Zhu H. (2021b). Study on antidepressant-like effect of protoilludane sesquiterpenoid aromatic esters from Armillaria Mellea. Nat. Prod. Res. 35 (6), 1042–1045. Epub 2019/05/29. 10.1080/14786419.2019.1614577 Zhao J. Zeng X. Liu J. Liu X. Liu Z. Wang B. (2023). Marasmius androsaceus mitigates depression-exacerbated intestinal radiation injuries through reprogramming hippocampal miRNA expression. Biomed. Pharmacother. 165, 115157. Epub 2023/07/17. 10.1016/j.biopha.2023.115157 Zhao S. Rong C. Gao Y. Wu L. Luo X. Song S. (2021). Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor. Appl. Microbiol. Biotechnol. 105 (23), 8675–8688. Epub 2021/10/31. 10.1007/s00253-021-11634-y Zhou L. L. Ming L. Ma C. G. Cheng Y. Jiang Q. (2005). Antidepressant-like effects of BCEF0083 in the chronic unpredictable stress models in mice. Chin. Med. J. Engl. 118 (11), 903–908. Glossary
FST forced swim test
TST tail suspension test
OVX ovariectomy
UCMS unpredictable chronic mild stress
CORT corticosterone
SPT sucrose preference test
CRS chronic restraint stress
CSDS chronic social defeat stress
STZ streptozotocin (-induced diabetes)
PSD post-stroke depression
MS maternal separation
LPS lipopolysaccharide
MCAO middle cerebral artery occlusion
HE Hericium erinaceus
Gl-E Ganoderma lucidum extract
EEGL ethanol extract of Ganoderma lucidum
GLP Ganoderma lucidum polysaccharide
MAK Ganoderma lucidum mycelia
GLT Ganoderma lucidum triterpenoid
AEGI aqueous extract of Ganoderma lucidum
PGL Polysaccharide-peptide of Ganoderma lucidum
GAA Ganoderic acid
PCE Psilocybe cubensis extract
PO Pleurotus ostreatus
EtOH ethanol
MEPS exopolysaccharide polysaccharide of Marasmius androsaceus
PCW Poria cocos water extract
WAM water extract of Armillaria mellea
PSAM Protoilludane sesquiterpenoid aromatic esters from Armillaria mellea
AWE Agaricus brasiliensis water extract
AC Antrodia cinnamomea
Er Ergosterol
CW Cordyceps militaris water extract
COR Cordycepin
PCM polysaccharide of Cordyceps militaris
PTNE Paecilomyces tenuipes N45 aqueous extract
AE alcohol extract
WE water extract
PHC Paecilomyces hepiali extract
OFE Ophiocordyceps formosana extract
BCEF bioactive compound from entomogenous fungi
IR intestinal radiation
E2 17β-estradiol
Dp depression
i.p. intraperitoneal
p.o. per os (oral)
i.g. intragastric
s.c. subcutaneous
i.v. intravenous